# wet AMD FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/wet-amd

> No upcoming FDA catalysts in wet AMD; 5 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for wet AMD?

No upcoming FDA catalysts in wet AMD; 5 past events are recorded. SEC prospectus (424B): "On July 24, 2026, we announced that the FDA approved LYTENAVA for the treatment of wet AMD." [Calendar and source filings](https://sec-api.dev/indications/wet-amd)

Source: SEC prospectus (424B), accession 0001104659-26-096504, https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm (retrieved 2026-11-12). Last confirmed 2026-08-14. Cite: https://sec-api.dev/indications/wet-amd#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2022 | [MVASI® (bevacizumab) NDA/BLA submission](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed | "Separately, in March 2022, we submitted a BLA to the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Inc (the "Company") issued a press release announcing that it has completed the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm)) |
| December 30, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22)) |
| December 31, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm)) |
| July 24, 2026 | [LYTENAVA™ (lytenava) FDA approval](https://sec-api.dev/pdufa/lytenava) | OTLK | wet AMD | completed, approved | "On July 24, 2026, we announced that the FDA approved LYTENAVA for the treatment of wet AMD." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm)) |

## Drugs

- [MVASI® (bevacizumab)](https://sec-api.dev/pdufa/bevacizumab) (OTLK)
- [LYTENAVA™ (lytenava)](https://sec-api.dev/pdufa/lytenava) (OTLK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/wet-amd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "wet AMD FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/wet-amd

```bibtex
@misc{secapidev_indications_wet_amd_20261116,
  title        = {wet AMD FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/wet-amd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_wet_amd_20261116","title":"wet AMD FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/wet-amd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
